[Lipid-lowering therapy in patients with coronary disease: proportion of patients requiring treatment according to recommendations of the Swiss Society of Cardiology].
Recent studies have confirmed that treatment with lipid-lowering drugs decreases cardiovascular morbidity and mortality in primary as well as secondary prevention of cardiovascular diseases. In 1999, new Swiss recommendations for treatment with lipid-lowering drugs have been published. We therefore performed a study to estimate the proportion of patients with coronary artery disease requiring lipid-lowering drugs. We included 637 patients with coronary heart disease who were referred for coronary angiography during 1991-1993. We calculated the proportion of patients requiring lipid-lowering drugs according to the new Swiss guidelines, and compared them with European and US guidelines. According to the 1999 Swiss recommendations, 79% of the study population would have qualified for lipid-lowering treatment (males 80%, females 78%; patients aged up to 69 years 80%, patients aged 70 years and over 73%). Agreement with both the Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention, and the ACC/AHA Guidelines for Management of Patients with Acute Myocardial Infarction, was 96% (Kappa 0.79 and 0.83 respectively). A large proportion of patients with coronary artery disease qualifies for treatment with lipid-lowering drugs. The new Swiss recommendations closely agree with European and US guidelines.